Jazz Pharmaceuticals
JAZZ
455 hedge funds and large institutions have $6.14B invested in Jazz Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 62 funds opening new positions, 160 increasing their positions, 164 reducing their positions, and 83 closing their positions.
62% more call options, than puts
Call options by funds: $27.7M | Put options by funds: $17.2M
2% less repeat investments, than reductions
Existing positions increased: 160 | Existing positions reduced: 164
1.62% less ownership
Funds ownership: 92.86% → 91.24% (-1.6%)
5% less funds holding
Funds holding: 480 → 455 (-25)
12% less capital invested
Capital invested by funds: $6.97B → $6.14B (-$829M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
25% less first-time investments, than exits
New positions opened: 62 | Existing positions closed: 83
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Swedbank
Stockholm,
Sweden
|
+$110M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$67.8M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$65.1M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$58M |
| 5 |
BG
Baupost Group
Boston,
Massachusetts
|
+$48.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$102M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$67.7M |
| 3 |
State Street
Boston,
Massachusetts
|
-$48.9M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$34M |
| 5 |
Morgan Stanley
New York
|
-$26.8M |
JAZZ Hedge Fund Activity: Q2 2024 in Review
455 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2024, worth a combined $6.14B — down 12% from $6.97B a quarter earlier.
Sellers outnumbered buyers: 83 funds closed out of JAZZ and 62 opened new positions — a net loss of 21 holders — while 164 trimmed existing stakes and 160 added.
The largest buyer was Swedbank, opening a new position worth an estimated $110M. The largest seller was BlackRock, cutting an estimated $102M.
- 455 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2024, down from 480 in Q1 2024.
- Funds reported $6.14B of Jazz Pharmaceuticals stock for Q2 2024, down 12% quarter-over-quarter.
- 62 funds opened new Jazz Pharmaceuticals positions in Q2 2024 and 83 closed out, a net change of -21 holders.
- The largest Jazz Pharmaceuticals buyer in Q2 2024 was Swedbank, an estimated $110M added.
- The largest Jazz Pharmaceuticals seller in Q2 2024 was BlackRock, an estimated $102M sold.
Based on aggregated 13F filings for Q2 2024.